Real‐world outcomes of NSCLC patients receiving tissue or circulating tumor DNA‐guided osimertinib treatment

Real‐world outcomes of NSCLC patients receiving tissue or circulating tumor DNA‐guided osimertinib treatment

Abstract Background Osimertinib yields significant tumor responses and durations of progression‐free survival (PFS) in patients with acquired T790M mutations. However, the evidence supporting liquid biopsy‐guided treatment is still limited. This study examined the real‐world benefits of osimertinib...

Full description

Bibliographic Details
Main Authors: Po‐Lan Su, Szu‐Chun Yang, Yi‐Lin Chen, Yi‐Lin Wu, Chia‐Ying Lin, Wei‐Yuan Chang, Yau‐Lin Tseng, Wu‐Wei Lai, Chung‐Liang Ho, Chien‐Chung Lin, Wu‐Chou Su
Format: Article
Language:English
Published: Wiley 2019-10-01
Series:Cancer Medicine
Subjects:
circulating tumor DNA
NSCLC
osimertinib
progression‐free survival
T790M mutation
Online Access:https://doi.org/10.1002/cam4.2485

Internet

https://doi.org/10.1002/cam4.2485

Similar Items